Oruka Therapeutics, Inc. (ORKA) Return on equity 2016–2023
Oruka Therapeutics, Inc. (ORKA) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-14.4%FY2023 · since FY2016: -74.1% → -14.4%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2023 | -14.4% | +9.4 pp |
| FY2022 | -23.8% | +14.0 pp |
| FY2021 | -37.9% | -16.9 pp |
| FY2020 | -20.9% | +51.1 pp |
| FY2019 | -72.0% | +59.5 pp |
| FY2018 | -131.5% | +48.4 pp |
| FY2017 | -180.0% | -105.9 pp |
| FY2016 | -74.1% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More ORKA financial trends
ORKA RevenueORKA Net incomeORKA Net marginORKA Gross profitORKA Gross marginORKA Operating incomeORKA Operating marginORKA Operating cash flowORKA Free cash flowORKA Capital expendituresORKA Stock buybacksORKA Dividends paidORKA Total assetsORKA Total liabilitiesORKA Shareholders’ equityORKA overview →